 |
Kettering General Hospital |
 |
| NHS Foundation Trust |
|
| Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
| Useful Links |
 Chemotherapy Services - KGH Intranet (KGH Only) |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
08.01 |
Cytotoxic drugs (0,0)
|
|
|
Side-effects of cytotoxic drugs
(0,1)
|
|
|
Drugs for cytotoxic-induced side-effects
(3,5)
|
|
08.01.01 |
Alkylating drugs
(8,5)
|
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(9,4)
|
|
08.01.03 |
Antimetabolites
(12,5)
|
|
08.01.04 |
Vinca alkaloids and etoposide
(4,7)
|
|
08.01.05 |
Other antineoplastic drugs
(15,5)
|
|
|
Amsacrine
(1,0)
|
|
|
CDK inhibitors (0,0)
|
|
|
Arsenic trioxide
(1,0)
|
|
|
Bevacizumab
(1,0)
|
|
|
Bexarotene
(0,1)
|
|
|
Bortezomib
(1,0)
|
|
|
Brentuximab vedotin
(1,0)
|
|
|
Cetuximab
(1,1)
|
|
|
Crisantaspase
(0,1)
|
|
|
Dacarbazine and Temozolomide
(1,1)
|
|
|
Erlotinib (0,0)
|
|
|
Hydroxycarbamide
(1,1)
|
|
|
Imatinab (0,0)
|
|
|
Mitotane
(0,1)
|
|
|
Panitumumab
(1,0)
|
|
|
Pentostatin
(0,1)
|
|
|
Platinum compounds
(3,1)
|
|
|
Porfimer sodium and temoporfin
(0,2)
|
|
|
Procarbazine
(1,0)
|
|
|
Protein kinase inhibitors
(21,11)
|
|
|
Tezanes
(2,2)
|
|
|
Topoisimerase I inhibitors
(2,1)
|
|
|
Trabectedin
(0,1)
|
|
|
Trastuzumab
(2,0)
|
|
|
Tretinoin
(1,0)
|
|
|
Vismodegib
(0,1)
|
|
08.02 |
Drugs affecting the immune response (0,0)
|
|
|
Immunosuppressant therapy
(1,0)
|
|
08.02.01 |
Antiproliferative immunosuppressants
(2,3)
|
|
08.02.02 |
Corticosteroids and other immunosuppressants
(5,11)
|
|
08.02.03 |
Anti-lymphocyte monoclonal antibodies
(9,0)
|
|
08.02.04 |
Other immunomodulating drugs
(7,2)
|
|
|
Interferon Alfa
(3,3)
|
|
|
Interferon beta
(4,2)
|
|
|
Interferon gamma (0,0)
|
|
|
Aldesleukin
(1,2)
|
|
|
BCG bladder instillation (0,0)
|
|
|
Canakinumab (0,0)
|
|
|
Dimethyl fumarate (0,0)
|
|
|
Fingolimod (0,0)
|
|
|
Glatiramer acetate
(1,0)
|
|
|
Histamine (0,0)
|
|
|
Lenalidomide, pomalidomide, and thalidomide
(1,0)
|
|
|
Mifamurtide (0,0)
|
|
|
Natalizumab
(0,1)
|
|
|
Teriflunomide (0,0)
|
|
08.03 |
Sex hormones and hormone antagonists in malignant disease (0,0)
|
|
08.03.01 |
Oestrogens
(2,0)
|
|
08.03.02 |
Progestogens
(3,1)
|
|
08.03.03 |
Androgens (0,0)
|
|
08.03.04 |
Hormone antagonists (0,0)
|
|
08.03.04.01 |
Breast cancer
(5,2)
|
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues
(0,1)
|
|
|
Gonadorelin analogues
(2,1)
|
|
|
Anti-androgens
(6,6)
|
|
|
Gonadotrophin-releasing hormone antagonists (0,0)
|
|
08.03.04.03 |
Somatostatin analogues
(3,1)
|
|
|
|
